Research reports on gene therapy from Tulane University, University Health Science Center provide new insights
2007 NOV 22 -- Researchers detail in 'Overexpression of p101 activates PI3Kgamma signaling in T cells and contributes to cell survival,' new data in gene therapy. According to a study from the United States, "p101, the regulatory subunit of phosphatidylinositol-3-kinase-gamma (PI3Kgamma), was recently reported as a common site of retroviral insertion in T-cell lymphomas induced in mice by MoFe2-MuLV, a unique recombinant gammaretrovirus. The common interruption of p101 by retroviral integration suggests that the locus encodes an oncogene whose altered expression is related to the induction of T-cell malignancy." "To examine a possible role in the malignant process, p101 was overexpressed in human T-cell lines Molt-4 and Jurkat. Transient overexpression of p101 induced apoptosis in recipient cells; however, stable expression could be established in cells that expressed moderate levels of p101. Constitutive p101 overexpression in those cells conferred significant protection against ultraviolet-induced apoptosis. Protection against apoptotic induction was attributed to p101-mediated activation of the Akt pathway. Constitutive overexpression of p101 enhanced the activity of p110gamma and further sensitized it to activation upon stimulation of G protein-coupled receptor. These findings are the first to implicate altered expression of p101 in malignancy, specifically in T-cell lymphoma," wrote C. Johnson and colleagues, Tulane University, University Health Science Center. The researchers concluded: "The findings further provide insight into the regulation of p110gamma, indicating that the stoichiometry of p110gamma and p101 are important in regulating PI3Kgamma signaling." Johnson and colleagues published their study in Oncogene (Overexpression of p101 activates PI3Kgamma signaling in T cells and contributes to cell survival. Oncogene, 2007;26(49):7049-57). For more information, contact C. Johnson, Tulane University Health Sciences Center, Dept. of Microbiology and Immunology and Tulane Cancer Center, New Orleans, LA USA.. Publisher contact information for the journal Oncogene is: Nature Publishing Group, Macmillan Building, 4 Crinan St., London N1 9XW, England. Keywords: United States, New Orleans, Biotechnology, Gene Therapy. This article was prepared by Genetics & Environmental Business Week editors from staff and other reports. Copyright 2007, Genetics & Environmental Business Week via NewsRx.com.
|
